MannKind Corporation (MNKD)
NASDAQ
Market Cap
$1.41B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
658 of 809
Rank in Industry
357 of 445
Largest Insider Buys in Sector
MNKD Stock Price History Chart
MNKD Stock Performance
About MannKind Corporation
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.
Insider Activity of MannKind Corporation
Over the last 12 months, insiders at MannKind Corporation have bought $0 and sold $1.32M worth of MannKind Corporation stock.
On average, over the past 5 years, insiders at MannKind Corporation have bought $259,276 and sold $1.2M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 3,147 shares for transaction amount of $9,221 was made by Castagna Michael (Chief Executive Officer) on 2022‑07‑31.
List of Insider Buy and Sell Transactions, MannKind Corporation
| 2024-05-21 | Sale | Binder Steven B. | EVP Special Projects | 25,952 0.0094% | $4.66 | $120,936 | -0.21% | |
| 2024-05-21 | Sale | Thomson David | EVP Genl Counsel & Secretary | 23,537 0.0085% | $4.66 | $109,682 | -0.21% | |
| 2024-05-13 | Sale | Binder Steven B. | EVP Special Projects | 3,618 0.0013% | $4.31 | $15,594 | +6.58% | |
| 2024-05-13 | Sale | Thomson David | EVP Genl Counsel & Secretary | 3,047 0.0011% | $4.31 | $13,133 | +6.58% | |
| 2023-12-15 | Sale | Castagna Michael | Chief Executive Officer | 90,482 0.0341% | $4.00 | $361,928 | +9.25% | |
| 2023-12-14 | Sale | Castagna Michael | Chief Executive Officer | 110,000 0.0409% | $4.00 | $440,000 | +8.16% | |
| 2023-11-01 | Sale | Castagna Michael | Chief Executive Officer | 10,000 0.0039% | $4.25 | $42,500 | +0.50% | |
| 2023-10-02 | Sale | Castagna Michael | Chief Executive Officer | 10,000 0.0038% | $4.08 | $40,800 | +0.99% | |
| 2023-09-01 | Sale | Castagna Michael | Chief Executive Officer | 10,000 0.0037% | $4.61 | $46,100 | -11.23% | |
| 2023-08-28 | Sale | Thomson David | EVP Genl Counsel & Secretary | 8,100 0.003% | $4.78 | $38,738 | -13.84% | |
| 2023-08-01 | Sale | Castagna Michael | Chief Executive Officer | 10,000 0.0039% | $4.57 | $45,686 | -7.35% | |
| 2023-07-05 | Sale | Castagna Michael | Chief Executive Officer | 5,586 0.0021% | $4.01 | $22,407 | +4.75% | |
| 2023-07-03 | Sale | Castagna Michael | Chief Executive Officer | 4,414 0.0017% | $4.07 | $17,965 | +5.28% | |
| 2023-06-01 | Sale | Castagna Michael | Chief Executive Officer | 10,000 0.0038% | $4.53 | $45,302 | -7.92% | |
| 2023-05-26 | Sale | Castagna Michael | Chief Executive Officer | 75,000 0.0281% | $4.50 | $337,335 | -9.25% | |
| 2023-05-25 | Sale | Castagna Michael | Chief Executive Officer | 75,000 0.0287% | $4.59 | $344,468 | -9.34% | |
| 2023-05-24 | Sale | Castagna Michael | Chief Executive Officer | 150,000 0.0565% | $4.69 | $702,780 | -12.31% | |
| 2023-05-24 | Sale | Binder Steven B. | Chief Financial Officer | 47,810 0.018% | $4.67 | $223,512 | -12.31% | |
| 2023-05-24 | Sale | Thomson David | EVP Genl Counsel & Secretary | 95,576 0.036% | $4.68 | $447,754 | -12.31% | |
| 2023-05-05 | Sale | Castagna Michael | Chief Executive Officer | 10,000 0.0038% | $4.00 | $40,000 | +4.04% |
Insider Historical Profitability
8.12%
| Castagna Michael | Chief Executive Officer | 2148665 0.7971% | $5.19 | 20 | 15 | +8.74% |
| Binder Steven B. | Chief Financial Officer | 1114553 0.311% | $5.19 | 9 | 3 | +23.89% |
| Thomson David | EVP Genl Counsel & Secretary | 873616 0.2963% | $5.19 | 0 | 63 | |
| MANN ALFRED E | Chairman & CEO | 74750000 27.7288% | $5.19 | 15 | 0 | <0.0001% |
| Edstrom Hakan | President & CEO | 1060302 0.3933% | $5.19 | 10 | 15 | +5.87% |
| Tross Stuart A | Chief People & Workpl Officer | 830650 0.3081% | $5.19 | 12 | 0 | +16.1% |
| Galindo Alejandro | EVP Endocrine Business Unit | 777090 0.2883% | $5.19 | 6 | 1 | +14.54% |
| HOOPER ANTHONY C | director | 338394 0.1255% | $5.19 | 1 | 0 | +48.09% |
| MUNDKUR CHRISTINE | director | 254493 0.0944% | $5.19 | 1 | 0 | +48.09% |
| Grancio Jennifer | director | 244815 0.0908% | $5.19 | 1 | 0 | +48.09% |
| KRESA KENT | director | 237589 0.0881% | $5.19 | 3 | 0 | <0.0001% |
| Richardson Peter C | Chief Scientific Officer | 122497 0.0454% | $5.19 | 0 | 2 | |
| McCauley Patrick | Chief Commercial Officer | 100433 0.0373% | $5.19 | 5 | 0 | +1.23% |
| Martens Juergen | Corporate VP and COO | 88776 0.0329% | $5.19 | 5 | 26 | +0.94% |
| PFEFFER MATTHEW J | director | 82617 0.0306% | $5.19 | 10 | 7 | +10.58% |
| COHEN ABRAHAM E | director | 56424 0.0209% | $5.19 | 0 | 1 | |
| ANDERSON RICHARD L | VP & CFO | 48440 0.018% | $5.19 | 2 | 1 | <0.0001% |
| Kendall David M | Chief Medical Officer | 41059 0.0152% | $5.19 | 5 | 0 | +28.17% |
| Ingram Elizabeth Garrett | Chief Marketing Officer | 31141 0.0116% | $5.19 | 1 | 0 | +3.17% |
| Alinaya Rosabel Realica | SVP, Investor Relations | 30091 0.0112% | $5.19 | 2 | 1 | +12.28% |
| Barton Courtney | Chief Compl & Privacy Officer | 29584 0.011% | $5.19 | 3 | 0 | +6.05% |
| Palumbo Diane | Vice President, Human Resource | 29105 0.0108% | $5.19 | 3 | 27 | <0.0001% |
| Urbanski Raymond W. | Corp VP, CMO | 2924 0.0011% | $5.19 | 0 | 1 | |
| Cheatham W Wendell | VP, Chief Medical Officer | 538 0.0002% | $5.19 | 2 | 4 | +0.78% |
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
| BlackRock | $97.97M | 7.94 | 21.63M | -3% | -$3.03M | <0.01 | |
| The Vanguard Group | $68.59M | 5.56 | 15.14M | -0.71% | -$488,782.47 | <0.01 | |
| State Street | $54.09M | 4.39 | 11.94M | -7.72% | -$4.53M | <0.01 | |
| Nitorum Fund LP | $45.66M | 3.7 | 10.08M | -6.94% | -$3.41M | 4.65 | |
| Avoro Capital Advisors Llc | $40.77M | 3.31 | 9M | 0% | +$0 | 0.49 | |
| Geode Capital Management | $27.31M | 2.21 | 6.03M | +3.15% | +$833,837.82 | <0.01 | |
| Fidelity Investments | $20M | 1.62 | 4.42M | -25.68% | -$6.91M | <0.01 | |
| D. E. Shaw & Co. | $12.24M | 0.99 | 2.7M | -9.6% | -$1.3M | 0.02 | |
| Nuveen | $12.18M | 0.99 | 2.69M | +174.13% | +$7.74M | <0.01 | |
| Northern Trust | $11.71M | 0.95 | 2.59M | -2.24% | -$268,610.86 | <0.01 | |
| Bank of America | $10.97M | 0.89 | 2.42M | +238.64% | +$7.73M | <0.01 | |
| Parkman Healthcare Partners Llc | $10.9M | 0.88 | 2.41M | -3.71% | -$419,876.64 | 1.35 | |
| Two Sigma | $10.88M | 0.88 | 2.4M | +136.75% | +$6.28M | 0.02 | |
| Eversept Partners LP | $10.83M | 0.88 | 2.39M | New | +$10.83M | 0.82 | |
| Morgan Stanley | $10.66M | 0.86 | 2.35M | +106.97% | +$5.51M | <0.01 | |
| Charles Schwab | $9.61M | 0.78 | 2.12M | +2.65% | +$248,262.11 | <0.01 | |
| Invesco | $8.97M | 0.73 | 1.98M | +11.96% | +$958,008.84 | <0.01 | |
| 180 Wealth Advisors LLC | $8.8M | 0.71 | 1.94M | +12.57% | +$982,466.37 | 1.63 | |
| Millennium Management LLC | $7.42M | 0.6 | 1.64M | +85.17% | +$3.41M | 0.01 | |
| Soleus Capital Management, L.P. | $7.06M | 0.57 | 1.56M | New | +$7.06M | 0.07 | |
| Two Sigma Advisers LP | $6.01M | 0.49 | 1.33M | +22.57% | +$1.11M | 0.01 | |
| Goldman Sachs | $5.41M | 0.44 | 1.19M | -60.78% | -$8.38M | <0.01 | |
| Connor Clark & Lunn Investment Management Ltd | $4.93M | 0.4 | 1.09M | +44.63% | +$1.52M | 0.01 | |
| Voya Investment Management LLC | $4.66M | 0.38 | 1.03M | -10.71% | -$559,314.51 | 0.01 | |
| Citadel Advisors LLC | $4.52M | 0.37 | 998,858 | -2.56% | -$118,948.72 | <0.01 | |
| Apollo Management Holdings L P | $4.37M | 0.35 | 964,113 | 0% | +$0 | 0.06 | |
| Schonfeld Group | $4.13M | 0.34 | 910,996 | -10.24% | -$470,630.66 | 0.03 | |
| Tsp Capital Management Group Llc | $3.66M | 0.3 | 808,100 | New | +$3.66M | 1.21 | |
| Marshall Wace | $3.65M | 0.3 | 805,123 | -58.47% | -$5.14M | 0.01 | |
| BNY Mellon | $3.62M | 0.29 | 799,858 | -9.24% | -$368,891.41 | <0.01 | |
| Oberweis Asset Management Inc | $3.62M | 0.29 | 798,800 | +10.52% | +$344,280.00 | 0.26 | |
| Rafferty Asset Management Llc | $3.32M | 0.27 | 732,111 | -10.4% | -$385,059.08 | 0.01 | |
| Wellington Management Company | $3.25M | 0.26 | 717,967 | +104.93% | +$1.67M | <0.01 | |
| UBS | $3.08M | 0.25 | 680,367 | -5.17% | -$168,135.45 | <0.01 | |
| Citigroup | $2.96M | 0.24 | 653,406 | +85.95% | +$1.37M | <0.01 | |
| Gsa Capital Partners Llp | $2.83M | 0.23 | 625,410 | +24.95% | +$565,721.21 | 0.23 | |
| Swiss National Bank | $2.4M | 0.19 | 528,900 | 0% | +$0 | <0.01 | |
| 1492 Capital Management, LLC | $2.33M | 0.19 | 513,394 | -0.69% | -$16,099.62 | 1.3 | |
| Cubist Systematic Strategies | $2.28M | 0.19 | 504,348 | +555.99% | +$1.94M | 0.02 | |
| Arrowstreet Capital, Limited Partnership | $2.07M | 0.17 | 456,232 | New | +$2.07M | <0.01 | |
| Wells Fargo | $1.92M | 0.16 | 423,253 | +3.17% | +$58,921.71 | <0.01 | |
| Deutsche Bank | $1.91M | 0.15 | 420,546 | +6.31% | +$113,086.90 | <0.01 | |
| Susquehanna International Group | $1.86M | 0.15 | 410,065 | -36.91% | -$1.09M | <0.01 | |
| RhumbLine Advisers | $1.71M | 0.14 | 377,519 | +2.15% | +$35,908.95 | <0.01 | |
| Ubs Asset Management Americas Inc | $1.71M | 0.14 | 377,918 | 0% | +$0 | <0.01 | |
| Raymond James Associates | $1.66M | 0.13 | 365,728 | -1.21% | -$20,312.52 | <0.01 | |
| Credit Suisse | $1.66M | 0.13 | 365,353 | 0% | +$0 | <0.01 | |
| ExodusPoint Capital Management, LP | $1.52M | 0.12 | 335,278 | +147.15% | +$904,383.06 | 0.02 | |
| Squarepoint Ops LLC | $1.34M | 0.11 | 295,804 | New | +$1.34M | 0.01 | |
| Jane Street Capital | $1.33M | 0.11 | 294,190 | -30.22% | -$577,167.43 | <0.01 |